Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 211 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drug Distribution Clear all
Terminated Phase 2 Interventional

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

NCT00417690
View directory record Official record
Conditions
Crohn's Disease
Interventions
4-Aminosalicylic acid, PASER placebo granules
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

NCT00712829
View directory record Official record
Conditions
Prostate Cancer
Interventions
123-I-MIP-1072, 123-I-MIP-1095
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

NCT01299285
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3009104
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption and Distribution of Glucosamine and Chondroitin

NCT00086229
View directory record Official record
Conditions
Osteoarthritis
Interventions
Glucosamine, Chondroitin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT03408470
View directory record Official record
Conditions
Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions
TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 28, 2026, 12:21 AM EDT
Active, not recruiting Not applicable Interventional

The Feasibility of Using the PulsePoint to Facilitate Overdose Education and Naloxone Distribution

NCT06523985
View directory record Official record
Conditions
Carrying Naloxone/Narcan on Their Person or in Their Vehicle, Being Trained to Respond to an Opioid Overdose
Interventions
Push messages (standard), Push messages (customized)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 4 Interventional Results available

Increasing Naloxone Access for Persons Who Use Opioids

NCT04303000
View directory record Official record
Conditions
Naloxone
Interventions
Opioid Overdose Education with Naloxone Distribution, Opioid Overdose Education
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Anniston, Alabama • Gadsden, Alabama • Mobile, Alabama + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01262963
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Not applicable Interventional

Choline PET/CT and MRI for Targeted Prostate Biopsy

NCT01751737
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Cancer Imaging
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

NCT01261754
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc MIP 1404, 99mTc MIP 1405
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 28, 2026, 12:21 AM EDT
Completed No phase listed Observational

Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity

NCT00029926
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
2-deoxy-2 [F-18] fluoro-2-d-glucose
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 12:21 AM EDT
Terminated Phase 1 Interventional

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

NCT00747825
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
131-I-MIP-1145
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 28, 2026, 12:21 AM EDT
Recruiting Phase 1 Interventional

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07733674
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
203Pb-RMX-VHPIB injection, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Radiomedix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

NCT00509301
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
131-I-chTNT-1/B MAB
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Phoenix, Arizona • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 28, 2026, 12:21 AM EDT
Completed No phase listed Observational

Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation

NCT01504373
View directory record Official record
Conditions
Respiratory Failure
Interventions
Neurally Adjusted Ventilatory Assist (NAVA)
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Month to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

NCT03703505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-348, [13C6]AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 28, 2026, 12:21 AM EDT
Not yet recruiting Not applicable Interventional

Homeless Overdose Prevention- Expansion

NCT07716202
View directory record Official record
Conditions
Homelessness, Opioid Education and Naloxone Distribution (OEND), Substance Use Disorder
Interventions
Homeless Overdose Prevention- Expansion (HOPE) - Low Intensity, Homeless Overdose Prevention- Expansion (HOPE) - High Intensity
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 12:21 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina

NCT00214747
View directory record Official record
Conditions
HIV Infections
Interventions
Vehicle gel formulations
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Not applicable Interventional Results available

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NCT00961233
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
inhaled/swallowed budesonide, viscous/swallowed budesonide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Calorie Deprivation on Adipose Tissue Distribution

NCT01658397
View directory record Official record
Conditions
Healthy
Interventions
Fasting
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 28, 2026, 12:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

NCT06087991
View directory record Official record
Conditions
Opioid Abuse
Interventions
Implementation of the BINDeR-Tx service model
Behavioral
Lead sponsor
Jerry Cochran
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 28, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

NCT00800956
View directory record Official record
Conditions
Healthy
Interventions
[14C]-esreboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 65 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Oct 28, 2026, 12:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rady Children's Institute Genomic Biorepository

NCT02917460
View directory record Official record
Conditions
Genetic Diseases
Interventions
Genomic sequencing and molecular diagnostic results, if any
Genetic
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
Not listed
Enrollment
102,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2050
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 28, 2026, 12:21 AM EDT